Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fortress Biotech Inc FBIO

Alternate Symbol(s):  FBIOP

Healthcare Biotechnology
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products and product candidates. The Company markets its various branded dermatology products, Qbrexza, Accutane, Amzeeq, Zilxi, Ximino, Exelderm and Targadox. Qbrexza (glycopyrronium 2.4%) is a medicated cloth towelette for the treatment of primary axillary... see more

Recent & Breaking News (NDAQ:FBIO)

Checkpoint Therapeutics Initiates Phase 1/2 Study of CK-101 – A Novel Third-Generation EGFR Inhibitor

GlobeNewswire October 3, 2016

Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference

GlobeNewswire September 23, 2016

Fortress Biotech Completes Tender Offer for Shares of National Holdings Corporation

GlobeNewswire September 12, 2016

Checkpoint Therapeutics Announces Acceptance of IND Application for CK-101 – A Novel Third Generation EGFR Inhibitor

GlobeNewswire August 11, 2016

Fortress Biotech Reports Second Quarter 2016 Financial Results and Recent Corporate Highlights

GlobeNewswire August 9, 2016

Journey Medical Corporation Launches Luxamend™ Wound Cream and Ceracade™ Skin Barrier Emulsion

GlobeNewswire July 25, 2016

Jubilant Biosys Enters into Exclusive out-Licensing Agreement with Checkpoint Therapeutics for Novel BET Inhibitors

GlobeNewswire May 27, 2016